Global Primary Immunodeficiency Therapeutic Market Growth (Status and Outlook) 2025-2031

The global Primary Immunodeficiency Therapeutic market size is predicted to grow from US$ 521 million in 2025 to US$ 732 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.

Primary immunodeficiencies are a group of different disorders in which part of the body"s immune system (mainly cells and proteins) is missing or does not function normally. As per researchers, estimated more than 300 different kinds of primary immunodeficiency disease (PIDD). The immune system is composed of white blood cells made in the bone marrow which protect and defend against attacks by foreign invaders such as bacteria, fungi, and germs. Antibodies and Complement are proteins that are made in response to infection or immunization and helps to fight against infections and plays a protective role in the immune system. In the most common primary immunodeficiency diseases, different forms of cells or proteins are missing or do not function which results in severe infections and/or infections that are unusually hard to cure. These infections may attack the respiratory system, the brain or spinal cord, the ears, skin, or in the urinary or gastrointestinal tracts. In some instances, primary immunodeficiency diseases target specific and/or multiple organs, glands, cells, and tissues. For example, heart defects are present in some primary immunodeficiency diseases.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LPI (LP Information)' newest research report, the “Primary Immunodeficiency Therapeutic Industry Forecast” looks at past sales and reviews total world Primary Immunodeficiency Therapeutic sales in 2024, providing a comprehensive analysis by region and market sector of projected Primary Immunodeficiency Therapeutic sales for 2025 through 2031. With Primary Immunodeficiency Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Primary Immunodeficiency Therapeutic industry.

This Insight Report provides a comprehensive analysis of the global Primary Immunodeficiency Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Primary Immunodeficiency Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Primary Immunodeficiency Therapeutic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Primary Immunodeficiency Therapeutic and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Primary Immunodeficiency Therapeutic.

This report presents a comprehensive overview, market shares, and growth opportunities of Primary Immunodeficiency Therapeutic market by product type, application, key players and key regions and countries.

Segmentation by Type:
Immunoglobulin Replacement Therapy
Stem Cell or Bone Marrow Transplantation
Antibiotic Therapy
Gene Therapy
Others

Segmentation by Application:
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Baxter International
Takeda Pharmaceutical
CSL Limited
Octapharma
Kedrion Biopharma
Bio Products Laboratory
LFB group
Grifols
Lupin Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.